Abstract 165P
Background
Lenvatinib is a new first-line molecular target drug for hepatocellular carcinoma (HCC) that is available worldwide. We evaluated the efficacy and safety of lenvatinib for unresectable HCC.
Methods
This study population included thirty-seven patients that we could follow from 42 patients who received lenvatinib between April 2018 and May 2019 in our hospital. We evaluated the lenvatinib treatment profile, the clinical response (according to mRECIST), adverse events (according to CTCAE v.4.0), progression free survival (PFS), overall survival (OS), conversion therapy and the tumor response after progressive disease (PD) and serious adverse events (sAEs).
Results
The study population included 34 male patients (91.9%). Eleven patients were positive for HBV, 14 were positive for HCV, 6 had a history of alcohol intake. The Child Pugh scores (CPS) were as follows: 5 (n = 27), 6 (n = 7), 7(n = 3). Fifteen patients had BCLC stage B and 22 had C. The reasons for lenvatinib included TACE failure/refractoriness (35.3%), vascular invasion (32%), extrahepatic spread: (27.0%), PD after other molecular target therapies (16.2%) . The initial dose was 12 mg (90%) in patients with a body weight of > 60 kg, 8 mg (68.8%) in patients with a body weight of < 60 kg; in these two groups, 50.0% and 66.6% of patients received a half-dose reduction after one month. The tumor responses were classified as follows: objective response rate (ORR), 35.1%; disease control rate (DCR), 70.3%; PFS, 7.3 months (95% CI 4.9-11.2); OS, the median OS was not reached. There was no significant differences in the CPS between before and after therapy (p = 0.68). The rates of AEs (any grade/grade ≥3) were as follows: hypertension (37.8/0%), protein urea (29.7/13.5%), hypothyroidism (16.2/0%), fatigue (8.1/2.7%), hand-foot skin reaction (5.4/0%), hepatic encephalopathy (8.1%), respectively. The ORR and DCR of the grade ≥3 and grade <2 groups did not differ to a statistically significant extent. In the grade ≥3 group, 4 patients obtained a clinical benefit, however could not receive chemotherapies because of a poor performance status (≥3).
Conclusions
Lenvatinib is good therapeutic drug for advanced HCC, however it is very important to pay attention to sAEs in patients who show a clinical benefit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract